Benign Prostatic Hyperplasia, Prostate Cancer, Urology, Urology / Urologic Surgery, Urology, Adult
Bio-Markers for Prostate Disease; Urologic surgery; Prostate cancer; Benign prostatic hyperplasia; Urology
Dr. Alan Partin is a professor of urology, oncology and pathology at the Johns Hopkins School of Medicine. His areas of clinical expertise include prognosis prediction for men with prostate cancer and treatment of benign prostatic hyperplasia with an emphasis on minimally invasive techniques. Dr. Partin serves as the David Hall McConnell Director of Urology and Urologist-in-Chief for the Department of Urology and Oncology.
Dr. Partin's research focuses on development and testing of new and existing methods for predicting the aggressiveness of prostate cancers. His laboratories have investigated many new serum tests, some of which are soon to become available for the diagnosis of prostate cancer as well as basics science investigation of new proteins, which may help in detection, and staging of prostate cancer.
Dr. Partin is credited with creating a set of tables widely known as the Partin Tables. These tables are based on accumulated data from hundreds of patients who had been treated for prostate cancer and are used to predict pathologic stage (the cancer stage as determined by a pathologist after surgery) from clinical (pre-surgery) variables. The accurate prediction of pathologic stage can help physicians and patients choose the most appropriate treatments.
He received his undergraduate degree in chemistry at the University of Mississippi. He earned his M.D. and Ph.D. in pharmacology and molecular systems from Johns Hopkins University School of Medicine. Dr. Partin also completed his residency in urology and surgery at The Johns Hopkins Hospital.
Dr. Partin has served on many advisory boards including the Sidney Kimmel Comprehensive Cancer Center Advisory Council and the NCI Early Diagnostic Research Network Executive Committee. He has been recognized with the Ambrose Monell Research Award, David Koch Prostate Cancer Research Award and the 2002 AUA/ACMI Gold Cystoscope Award, among others. He is a member of the American Medical Association and the American Urological Association.